Significance of Positive Urine Cytology on Progression and Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer

被引:9
作者
Koga, Fumitaka [1 ]
Kobayashi, Shuichiro [1 ]
Fujii, Yasuhisa [1 ]
Ishioka, Junichiro [1 ]
Yokoyama, Minato [1 ]
Nakanishi, Yasukazu [1 ]
Matsuoka, Yoh [1 ]
Numao, Noboru [1 ]
Saito, Kazutaka [1 ]
Masuda, Hitoshi [1 ]
Kihara, Kazunori [1 ]
机构
[1] Tokyo Med & Dent Univ, Dept Urol, Grad Sch, Tokyo, Japan
关键词
Cancer-specific survival; Progression; Urinary bladder; Urothelial carcinoma; Voided urine cytology; BACILLUS-CALMETTE-GUERIN; RISK; RECURRENCE; USA;
D O I
10.1016/j.clgc.2013.07.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This prospective study, consisting of 326 patients with non-muscle-invasive bladder cancer (NMIBC) who underwent 597 tumor resections, demonstrated that a voided urine cytology result that is positive for atypical cells is a predictor of disease progression, independent of histological grade. Time-dependent covariate Cox models appear more sensitive in detecting risk factors for NMIBC progression than conventional time-fixed models. Voided urine cytology may be useful for NMIBC risk stratification. Background: Positive results from voided urine cytology (VUC) indicate the fragility of the intercellular adhesion of bladder cancer cells, a critical biological process for invasion and metastasis, along with the presence of atypical cells. Few studies have focused on the prognostic role of VUC in non-muscle-invasive bladder cancer (NMIBC). Methods: Between 2000 and 2010, 326 patients diagnosed pathologically with Ta or T1 bladder urothelial carcinoma underwent 597 transurethral resections of bladder tumor (TURBTs). Clinicopathological data were prospectively collected at each TURBT. Reports of cells of class IIIb or greater were considered positive VUC results. Muscle-invasive or metastatic recurrences were considered progression. Risk factors for progression and cancer-specific mortality (CSM) were determined using time-fixed and time-dependent Cox models. Variables at the study entry and at each TURBT were used for time-fixed and time-dependent models, respectively. Results: The 5-year cumulative progression and CSM rates were, respectively, 7% and 5% (median follow-up, 46 months). The 5-year cumulative progression and CSM rates for patients with positive VUC were 20% and 15%, respectively, compared with 2% (P < .0001) and 2% (P = .0002), respectively, for patients with negative VUC results. A positive VUC result was a significant and independent risk factor for progression and CSM in the time-fixed and time-dependent models. In time-dependent models, 7 predictors for progression or CSM were identified (positive VUC results, T1 disease, lack of intravesical instillation, higher prior recurrence rate, higher histological grade, male gender, and advanced age), whereas 3 predictors were identified in time-fixed models (positive VUC, T1 disease, and higher prior recurrence rate). VUC results consistently outperformed histological grade as a prognostic predictor. Conclusion: Positive VUC results predict the progression and CSM of NMIBC, independent of and outperforming histological grade.
引用
收藏
页码:E87 / E93
页数:7
相关论文
共 22 条
[11]   Comparison of time trends in bladder cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII [J].
Matsuda, Tomohiro ;
Katanoda, Kota .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (01) :85-86
[12]   Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer [J].
McConkey, David J. ;
Choi, Woonyoung ;
Marquis, Lauren ;
Martin, Frances ;
Williams, Michael B. ;
Shah, Jay ;
Svatek, Robert ;
Das, Aditi ;
Adam, Liana ;
Kamat, Ashish ;
Siefker-Radtke, Arlene ;
Dinney, Colin .
CANCER AND METASTASIS REVIEWS, 2009, 28 (3-4) :335-344
[13]   Primary superficial bladder cancer risk groups according to progression, mortality and recurrence [J].
Millán-Rodríguez, F ;
Chéchile-Toniolo, G ;
Salvador-Bayarri, J ;
Palou, J ;
Algaba, F ;
Vicente-Rodríguez, J .
JOURNAL OF UROLOGY, 2000, 164 (03) :680-684
[14]  
Mostofi FK., 1973, HISTOLOGICAL TYPING
[15]   Cancer death from non-muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999-2001 registry in Japan [J].
Okajima, Eijiro ;
Fujimoto, Hiroyuki ;
Mizutani, Yoichi ;
Kikuchi, Eiji ;
Koga, Hirofumi ;
Hinotsu, Shiro ;
Shinohara, Nobuo ;
Miki, Tsuneharu .
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (11) :905-912
[16]  
PAPANICOLAOU GN, 1954, ATLAS EXOFOLIATIVE C
[17]   Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy [J].
Schrier, BP ;
Hollander, MP ;
van Rhijn, BWG ;
Kiemeney, LALM ;
Witjes, JA .
EUROPEAN UROLOGY, 2004, 45 (03) :292-296
[18]  
Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
[19]   Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials [J].
Sylvester, RJ ;
van der Meijden, APM ;
Lamm, DL .
JOURNAL OF UROLOGY, 2002, 168 (05) :1964-1970
[20]   Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials [J].
Sylvester, RJ ;
van der Meijden, APM ;
Oosterlinck, W ;
Witjes, JA ;
Bouffioux, C ;
Denis, L ;
Newling, DWW ;
Kurth, K .
EUROPEAN UROLOGY, 2006, 49 (03) :466-477